伊克力西斯 2025年季度报告

For the transion period from toCommission File Number:000-30235 Delaware(State or other jurisdicon of incorporaon or organizaon) Non-acceleratedfiler☐SmallerreporngcompanyEmerging growth company new or revisedfinancial accounng standards provided pursuant to Secon 13(a) of the Exchange Act.¨Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐Noý INDEXPART I - FINANCIAL INFORMATION Financial StatementsCondensed Consolidated Balance Sheets (Unaudited) Condensed Consolidated Statements of Comprehensive Income (Unaudited)Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) Condensed Consolidated Statements of Cash Flows (Unaudited)Notes to Condensed Consolidated Financial Statements (Unaudited) PART II - OTHER INFORMATIONUnregistered Sales of Equity Securies and Use of Proceeds SIGNATURES2 EXELIXIS, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(in thousands, except per share data)(unaudited) accounng principles for completefinancial statements. In our opinion, all adjustments (consisng only of normal recurring adjustments)considered necessary for a fair presentaon of ourfinancial statements for the periods presented have been included. Operang results for the six months ended June 30, 2025 are not necessarily indicave of the results that may be expected for the year ending December31, 2025or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjuncon with our Consolidated Financial Statements and Notes thereto for thefiscal year ended December31, 2024, included in PartII, Item8 of ourAnnual Report on Form10-K,filed with the SEC on February11, 2025 (Fiscal2024 Form10-K). The preparaon of the accompanying Condensed Consolidated Financial Statements conforms to accounng principles generallyaccepted in the U.S., which requires management to make judgments, esmates and assumpons that affect the reported amounts of assets, liabilies, equity, revenues and expenses and related disclosures. On an ongoing basis, we evaluate our significant esmates. We base ouresmates on historical experience and on various other market-specific and other relevant assumpons that we believe to be reasonableunder the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilies that arenot readily apparent from other sources. Actual results could differ materially from those esmates. Certain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conformto the current period presentaon. Such reclassificaons did not impact previously reported total revenues, income from operaons, net income, total assets, total liabilies or total stockholders’ equity.Significant Accounng Policies to the significant accounng policies disclosed in “Note 1. Organizaon and Summary of Significant Accounng Policies” of the “Notes toConsolidated Financial Statements” included in Part II, Item8 of our Fiscal2024 Form 10-K.Recently Adopted Accounng Pronouncements Recent Accounng Pronouncements Not Yet AdoptedIn December 2023, the Financial Accounng Standards Board (FASB) issued Accounng Standards Update (ASU) 2023-09,IncomeTaxes (Topic 740): Improvements to Income Tax Disclosures(ASU 2023-09), which enhances the disclosures required for income taxes in ourannual consolidatedfinancial statements. ASU 2023-09 is effecve for us in our annual reporng forfiscal 2025 on a prospecve basis. Earlyadopon and retrospecve reporng are permied. We are currently evaluang the impact of ASU 2023-09 on our Consolidated FinancialStatements. We operate inonebusiness segment that focuses on the discovery, development and commercializaon of new medicines fordifficult-to-treat cancers. Our President and Chief Execuve Officer, as the chief operang decision-maker, manages and allocates resources to our operaons on a total consolidated basis. Consistent with this decision-making process, our President and Chief Execuve Officer uses netincome to monitor budget versus actual results for purposes of evaluang performance and to make decisions about the allocaon of Our significant segment expenses that are regularly provided to our President and Chief Execuve Officer and included in themeasure of segment net income consist of consolidated expenses for our operaonal departments: drug discovery, development, and selling,general and administrave and other segment items. 2025202420252024$568,261$637,178$1,123,708$ Drug discoveryDevelopment Selling, general, and administrave112,931115,839233,706Other segment items66,71856,755124,134(1) Interest incomeProvision for income taxes Segment and consolidated net income$184,848$226,116$344,464$_________________Other segment items include stock-based compensaon, restructuring expenses, other research and development expen